Barclays
OGEN icon

Barclays’s Oragenics OGEN Stock Holding History

Barclays’s Portfolio OGEN Stock Details OGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Hold
0
– -$1K – 5025
2021
Q1 		– Hold
0
– – – 4601
2020
Q3 		– Hold
0
– – – 5470
2020
Q2 		– Sell
-95
Closed -$93.5K – 6060
2020
Q1 		$99K Sell
95
-91
-49% -$87.4K ﹤0.01% 4808
2019
Q4 		$175K Buy
186
+19
+11% +$16.9K ﹤0.01% 5131
2019
Q3 		$162K Buy
167
+56
+50% +$46.8K ﹤0.01% 5120
2019
Q2 		$98K Buy
111
+14
+14% +$12.8K ﹤0.01% 5712
2019
Q1 		$103K Buy
97
+22
+29% +$34.6K ﹤0.01% 5338
2018
Q4 		$116K Buy
75
+37
+97% +$72.5K ﹤0.01% 4938
2018
Q3 		$79K Buy
38
+30
+375% +$34.6K ﹤0.01% 5757
2018
Q2 		$20K Buy
8
+7
+700% +$18.4K ﹤0.01% 6193
2018
Q1 		$4K Buy
+1
New +$3.7K ﹤0.01% 6821

Other funds holding OGEN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SBF
Sara-Bay Financial Sarasota, Florida $375M AUM 56.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Barclays's OGEN Position: Q2 2021 in Review

Barclays held its Oragenics (OGEN) position steady in Q2 2021 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5025.

Barclays first reported a position in OGEN in Q1 2018 and has held it in 9 quarters since. The position peaked at $175K in Q4 2019. 17 funds tracked by Wall St. Rank hold OGEN as of Q2 2021.

  • Barclays held 0 shares of Oragenics worth $0 as of Q2 2021.
  • Barclays left its Oragenics share count unchanged in Q2 2021.
  • Oragenics made up ﹤0.01% of Barclays's portfolio in Q2 2021, its #5025 holding.
  • Barclays first reported a position in Oragenics in Q1 2018 and has held it in 9 quarters since.
  • Barclays's Oragenics position peaked at $175K in Q4 2019.
  • 17 funds tracked by Wall St. Rank held Oragenics as of Q2 2021.

Based on Barclays's 13F filing for Q2 2021, filed 13 Aug 2021.